.png)
Agenzia Italiana del Farmaco
Direct communication with healthcare professionals on Xagrid (anagrelide hydrochloride) - Direct communication with healthcare professionals on Xagrid (anagrelide hydrochloride)
Direct communication with healthcare professionals on Xagrid (anagrelide hydrochloride)
Summary:
- There is an increased risk of thrombotic complications, including cerebral infarction, upon abrupt anagrelide discontinuation.
- Abrupt treatment discontinuation should be avoided due to the risk of sudden increase in platelet counts and potentially fatal thrombotic complications, such as cerebral infarction.
- In the event of dosage interruption or treatment withdrawal, monitor platelet counts frequently (refer to SmPC Section 4.4).
- Advise patients how to recognize early signs and symptoms suggestive of thrombotic complications, such as cerebral infarction, and if symptoms occur to seek medical assistance.
Published on: 22 February 2022
📍 #AIFA sul territorio: a Genova la prossima tappa
Dopo Milano e Palermo, AIFA fa tappa a Genova pe...
Vai al post →
🔬 Promuovere la cultura della ricerca clinica nella Medicina Generale
È disponibile, online e gratu...
Vai al post →
💊 Farmacovigilanza attiva: bando per progetto nazionale dedicato a #pazienti anziani, multicronici ...
Vai al post →
From across Europe to Rome to discuss #OrphanMedicines and #RareDiseases
The meeting of the Committ...
Vai al post →
📍AIFA partecipa alla nona edizione dei Seminari di Mogliano Veneto
Due giornate di confronto sull’...
Vai al post →
📢 Il CdA di #AIFA dà il via libera alla rimborsabilità di 2 nuovi #farmaci orfani per il trattament...
Vai al post →
